Biomunex Partners with AI Companies to Accelerate Bispecific Antibody Discovery in Cancer Immunotherapy
核心洞察
Biomunex Pharmaceuticals (搜索) announced strategic collaborations with Gordion Bioscience (搜索) and Tangramed Biotech (搜索) to integrate artificial intelligence into its bispecific antibody discovery and development processes.
The partnerships aim to identify novel target combinations for cancer immunotherapy using AI-driven computational approaches and generative AI technologies.
These collaborations leverage Biomunex's proprietary BiXAb platform, which enables rapid generation of bispecific antibodies from monoclonal antibody pairs.
Biomunex Pharmaceuticals (搜索) has announced two strategic artificial intelligence collaborations designed to accelerate the discovery and development of its innovative cancer immunotherapy pipeline. The biopharmaceutical company, based in Paris, France, and Cambridge, Massachusetts, has partnered with Gordion Bioscience (搜索) and Tangramed Biotech (搜索) to integrate AI capabilities into its research and development processes for bispecific and multi-specific antibodies.
AI-Driven Target Discovery Partnerships
Under the first collaboration, Biomunex will work with Gordion Bioscience (搜索), a US-based AI-driven oncology company specializing in patient-derived biological network analysis and computational target discovery. The partnership aims to identify novel bispecific target combinations in oncology, with the objective of reinforcing Biomunex's innovative pipeline with original pairs of targets and new differentiated therapeutic candidates for cancer treatment.
"Gordion's framework uncovers co-essential target pairs that conventional expression-based approaches often fail to detect," said Dr. Pawel Zawadzki, CEO of Gordion Bioscience (搜索). "Gordion will systematically explore a broad landscape of target combinations, surfacing clinically differentiated pairs for breakthrough bispecific antibodies."
Generative AI for Therapeutic Discovery
The second collaboration involves Tangramed Biotech (搜索), a France-based AI-enabled biotech company developing multimodal target-combination discovery approaches powered by biomedical data analytics. This partnership is expected to leverage generative AI for the identification of novel therapeutic candidates in solid tumors and hematological malignancies, focusing on target combinations that could utilize Biomunex's proprietary BiXAb platforms.
Dr. Jinchao Yu, CSO of Tangramed Biotech (搜索), commented: "By combining our AI-driven platform with Biomunex's BiXAb technologies, we believe that Tangramed will help Biomunex further accelerate the identification of high-value target combinations to create next-generation immunotherapies in oncology."
Strategic Integration of AI Technology
These collaborations reflect Biomunex's commitment to combining its proprietary platform technologies with AI capabilities across several R&D axes, particularly to optimize target selection, shorten discovery timelines, and increase the probability of translational success.
"Artificial intelligence has become a major driver of innovation in drug discovery," said Dr. Simon Plyte, CSO of Biomunex. "By combining our expertise in bispecific and multi-specific antibodies and our BiXAb platforms with the technologies developed by AI-driven companies, such as Tangramed Biotech (搜索) and Gordion Bioscience (搜索), we are strengthening our ability to rapidly identify new therapeutic opportunities in oncology."
BiXAb Platform Technology
Biomunex has developed BiXAb, described as a robust, next-generation, plug-and-play technology platform for bi- and multi-specific antibodies using a proprietary in silico modeling approach. The platform enables the generation of bispecific antibodies from any pair of monoclonal antibodies in a simple, rapid, and cost-effective manner, and has been validated through licensing agreements and collaborations with pharmaceutical and biotechnology companies, including Sanofi, Onward Therapeutics (搜索), and Ipsen.
The company is notably the first in the world to develop a cancer immunotherapy approach that uses bispecific antibodies from its BiXAb platform to specifically target, engage, and redirect MAIT cells, a subpopulation of T cells naturally present throughout the body, particularly in mucosal and barrier tissues, to kill cancer cells for the treatment of solid tumors.
Broader AI Integration Strategy
Dr. Pierre-Emmanuel Gerard, Founding President and CEO of Biomunex, emphasized the strategic importance of these partnerships: "These deals represent a step forward in our AI strategy, to accelerate even more our process to generate and develop new breakthrough clinical candidates." The company plans to integrate AI not only in R&D programs but also in general corporate resources, including finance, accounting, human resources recruitment, and legal topics.